Clinical Trial Update: Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed and/or sunitinib as second-line therapy in patients with stage IIIB or stage IV non-small cell lung cancer; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2015-03-19